Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Summary

To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have residual disease following induction therapy.

Timeline

Start

2021-12-01

Primary completion

2022-08-04

Completion

2022-11-03

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Drugs

Indications